Logo

Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

Share this

Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

Shots:

  • Thermo Fisher and NX Prenatal enter into a collaboration to develop proteomics assays by combining NX Prenatal's NeXosome platform with Thermo Fisher's LC-MS instrumentation for monitoring the maternal & fetal health and evaluating the risk of complications
  • The focus of the collaboration is to provide a diagnostic solution to both clinical and medical professionals by evaluating maternal and fetal biomarkers during pregnancy and to assess adverse outcomes including preterm birth and preeclampsia for improving health
  • NX Prenatal's NeXosome technology harvest microparticles (exosomes) from the mother’s blood- maintaining the balance between mother & fetus during the pregnancy

Ref: Thermo Fisher | Image: Evaluating Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions